SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk

Schernthaner, Guntram; Groop, Per-Henrik; Kalra, Philip A.; Ronco, Claudio; Taal, Maarten W.

Abstract

Data from three completed cardiovascular outcome trials (CVOTs), EMPA‐REG OUTCOME, CANVAS Program and DECLARE‐TIMI 58, add to the evidence supporting the potential renoprotective effects of sodium‐glucose linked transporter‐2 (SGLT2) inhibitors in patients with type‐2 diabetes (T2D). Despite recommendations in recent guidelines, it is difficult to support a view that definitive evidence for renoprotection exists from these SGLT2 inhibitor CVOT results. To date, the only dedicated trial to report definitive data on the renal impact of SGLT2 inhibition is CREDENCE. Notably, the total number of patient relevant renal endpoint events (dialysis, transplant or renal death) observed in CREDENCE was significantly higher than the total for all three CVOTs collectively (183 events/4,401 patients vs. 69 events/34,322 patients, respectively), which demonstrates the increased statistical power of CREDENCE for these renal endpoints. Treatment with canagliflozin was associated with a 30% relative risk reduction (RRR) in the primary composite endpoint of end‐stage kidney disease, doubling of serum creatinine, or death from renal or cardiovascular causes and a 34% RRR for the renal‐specific elements of this primary endpoint (P

Citation

Schernthaner, G., Groop, P.-H., Kalra, P. A., Ronco, C., & Taal, M. W. (2020). SGLT‐2 Inhibitor Renal Outcome Modification in Type‐2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk. Diabetes, Obesity and Metabolism, 22(7), 1024-1034. https://doi.org/10.1111/dom.13994

• Journal Article Type: Article
• Acceptance Date: Feb 4, 2020
• Online Publication Date: Feb 9, 2020
• Publication Date: 2020-07
• Deposit Date: Feb 6, 2020
• Publicly Available Date: Feb 10, 2021
• Journal: Diabetes, Obesity and Metabolism
• Print ISSN: 1462-8902
• Electronic ISSN: 1463-1326
• Publisher: Wiley
• Peer Reviewed: Peer Reviewed
• Volume: 22
• Issue: 7
• Pages: 1024-1034
• DOI: https://doi.org/10.1111/dom.13994
• Keywords: Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
• Public URL: https://nottingham-repository.worktribe.com/output/3909298
• Publisher URL: https://onlinelibrary.wiley.com/doi/abs/10.1111/dom.13994
• Additional Information: Received: 2019-12-05; Accepted: 2020-02-04; Published: 2020-02-09